Status | Study |
Completed |
Study Name: Titrating-Dose of Lonafarnib in Combination With Ritonavir Condition: Chronic Delta Hepatitis Date: 2015-08-13 Interventions: Drug: lonafarnib antiviral far |
Completed |
Study Name: Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Condition: Hepatitis D Date: 2015-07-29 Interventions: Drug: Lonafarnib prenylation i |
Recruiting |
Study Name: Lonafarnib With Ritonavir in HDV (LOWR-2) Condition: Chronic Hepatitis D Infection Date: 2015-04-21 Interventions: Drug: lonafarnib antiviral far |
Completed |
Study Name: Lonafarnib With and Without Ritonavir in HDV (LOWR-1) Condition: Chronic Hepatitis D Infection Date: 2015-04-21 Interventions: Drug: lonafarnib antiviral far |
Recruiting |
Study Name: The Hepatitis Delta International Network Condition: Hepatitis D Date: 2015-02-19 |
Active, not recruiting |
Study Name: REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection Condition: Chronic HBV Infection (HBeAg Negative) Date: 2014-09-01 Interventions: Drug: REP 2139-Ca + Pegasys (TM) 15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139 |
Completed |
Study Name: Mother-to-child Hepatitis D Transmission Condition: Hepatitis D Transmission Date: 2014-01-18 |
Terminated |
Study Name: An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a) Condition: Hepatitis D, Chronic Date: 2013-05-02 |
Completed |
Study Name: Lonafarnib for Chronic Hepatitis D Condition: Hepatitis D Date: 2011-12-16 Interventions: Drug: Lonafarnib Commercially |
Terminated |
Study Name: Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) Condition: Hepatitis D Date: 2011-03-14 Interventions: Drug: EBP921 Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with |